gadolinium dtpa has been researched along with Phobic Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frezza, F; Longo, R; Magnaldi, S; Pozzi-Mucelli, RS; Razavi, IS; Ukmar, M | 1 |
| Kanal, E; Shellock, FG; Talagala, L | 1 |
1 review(s) available for gadolinium dtpa and Phobic Disorders
| Article | Year |
|---|---|
Safety considerations in MR imaging.
Topics: Accident Prevention; Contrast Media; Electromagnetic Fields; Gadolinium DTPA; Heart; Helium; Humans; Magnetic Resonance Imaging; Magnetics; Noise; Organometallic Compounds; Pentetic Acid; Phobic Disorders; Radio Waves; Safety; United States; United States Food and Drug Administration | 1990 |
1 other study(ies) available for gadolinium dtpa and Phobic Disorders
| Article | Year |
|---|---|
Assessment of pituitary microadenomas: comparison between 2D and 3D MR sequences.
Topics: Adult; Aged; Artifacts; Contrast Media; Evaluation Studies as Topic; Female; Follow-Up Studies; Gadolinium; Gadolinium DTPA; Humans; Hyperprolactinemia; Image Enhancement; Injections, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Pentetic Acid; Phobic Disorders; Pituitary Neoplasms; Prolactinoma; Prospective Studies; Time Factors | 1997 |